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CDiscussion
r John A. Kern (Charlottesville, Va). John, that was a very nice
tudy that gives us more insight into the molecular biology of
scending aortic aneurysm pathology. As you detailed in your
anuscript, but not so much here because of time constraints, your
esults really parallel those of others. However, your study goes a
it further in showing us various activity profiles even among
neurysms of different sizes, which is quite interesting.
The main questions I have, to bring this into some clinical
ppreciation, is what does this study really do in furthering our
nderstanding of the natural history of ascending aortic aneurysms,
nd will findings such as these ultimately change the way we
pproach aneurysms, particularly with respect to timing of repair?
I also have a few nuts-and-bolts questions. The patients in the
ontrol group were quite a bit younger than those in the other
roups, and it makes us wonder about the biology of MMPs in
eneral, so could you just talk a bit about that. Also, your findings
ay have a genetic basis. Did you see any differences in profiles
ith respect to gender?
In addition, there is potentially a lot of differing medical
herapy in these patients, so I’m wondering, as the patients weren’t
ontrolled for things like antihypertensive therapy and antilipid
herapy, could those factors have had an impact on your results?
And last, obviously what we’re all interested in is trying to
gure out which patients are getting ready to have an aortic
atastrophe. So is there any way we can use these results—in other
ords, are any of these molecules considered such acute phase–
ype reactants, that we could somehow formulate an assay,
hether it be a serum assay or an imaging test, that we could use
o find those patients who are getting ready to become unstable?
nd then, if so, could we use these concepts to formulate some
orm of therapy, whether it be through conventional techniques or
ndovascular techniques?
Dr John S. Ikonomidis (Charleston, SC). Thank you, Dr Kern,
or raising those very pertinent issues. In answer to your overall
uestion, I think that we continue to further our knowledge about
iology of ATAA disease; specifically, we are starting to tease out
olecular pathways and effectors not just for 1 aneurysm type but
ow among various pathologic types.
I think that the present study adds to previous studies in the
ense that we have examined a broader range of MMPs and TIMPs
nd provided, perhaps, a larger profile. And in addition, we have
ad somewhat of a larger sample size, which allowed some cor-
elations to be made to aneurysm size, although I should preface
hat by saying that Dr Fedak has already demonstrated at the P 
05 level an association between MMP-2 and bicuspid ascending
ortic aneurysms.
As far as age is concerned, there is no doubt that age within the
ardiovascular system has an effect on MMP biology. And this is
confounding factor in this study that would be difficult to
emove. This point is offset, to some extent, by the fact that we t
036 The Journal of Thoracic and Cardiovascular Surgery ● Aprere able to examine specific aneurysm types by size within each
roup.
MMPs, in general, are not considered acute-phase reactants.
hey are extremely tightly regulated molecules that are active in
oth healthy and diseased states. In our animal model, we saw
pregulation of MMP-2 and MMP-9 within approximately 72
ours of an aneurysm stimulus.
As far as gender is concerned, we did analyze these results by
ender and found no statistical differences.
There are certain medical therapies that would modify MMP
ctivity. For example, treatment of these patients with beta-
lockers and the resultant decrease in shear stresses and dP/dt
ould decrease certain MMPs that are stress dependent, partic-
larly MMP-2. This could have a significant impact in therapy
or these aneurysms, much the same as there is a salutary effect
n Marfan’s syndrome.
None of these aneurysms came from patients who had an
mpending catastrophe, so I’m not able to provide profiles to you
bout those particular patients; however, development of specific
lasma or radiologic imaging strategies may allow us to charac-
erize the MMP profiles over time such that with further study, we
ay be able to identify a specific MMP and TIMP cassette that
ay indicate an impending rupture or a change in the character of
he aneurysm. And to that end, enzyme-linked immunosorbent
ssay tests are already being developed for following MMPs and
IMPs such as MMP-9, MMP-2, and TIMP-1 post–myocardial
nfarction, such that these may also be an option for following
atients with thoracic aortic aneurysm disease.
Furthermore, radiolabeled short-acting inhibitors, either global
r specific, bind within the cardiovascular system and can be
maged. We may be able to use these for serial imaging to follow
ither global MMP activity or specific MMPs as we tease out the
ifferent MMP profiles within the different aneurysm groups.
And finally, how can we make this work for us? These data
ay help us with diagnosis and prognostication. Also, novel
herapeutic strategies could include development of specific MMP
nhibitors that target 1 MMP or a specific subgroup of MMPs out
f the 26 known species, thus reducing the side-effect profiles that
re classically seen with global MMP inhibition. Obviously, gene
herapy is also a possibility.
Endovascular stent grafting is a very hot therapeutic modality
ight now; but a potential problem with this treatment modality is
hat the stent-grafted aorta likely continues to remodel. Thus, over
ime, the stent graft may fail through continued remodeling of the
neurysm and aorta both proximal and distal to the stent-graft. It
herefore may be valuable to place MMP inhibitors within the
abric of the aneurysm to arrest remodeling and thus increase the
ongevity of the stent-graft repair.
Dr Doosang Kim (Seoul, Korea). My question is about the
ocation of the sample site. Where is the most common location of
he sample site?
Dr Ikonomidis. The sample site was taken at the point where
he aneurysm was largest by inspection at the time of resection.
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